Maynard Um
-
-
-
-
-
-
-
INmune Bio receives FDA alignment on phase 2b/3 trial design for alzheimer's drug
-
-
-
-
-
-
-
BTIG Downgrades INmune Bio Inc. (INMB) to Neutral
-
-
-
-
-
-
-
After-hours movers: Nike, American Outdoor Brands and more
-
-
-
-
-
-
-
INmune Bio (INMB) Receives Favorable Patentability Opinion for CORDStrom Platform Technology
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)
-
-
-
-
-
-
-
INmune Bio (INMB) Reports Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial
-
-
-
-
-
-
406,886 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

